RxDoctor Payments Data

Charles Braucher, MD

Internal Medicine · Athens, GANPI 1629007216

Payments from drug & device makers

$7,162in general payments, 2019–2025

Across 427 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$932
  • Amgen$831
  • AstraZeneca$438
  • Supernus Pharmaceuticals, Inc.$344
  • Pfizer$334
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,138100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,162 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$137,887
Medicare patients
266
Services billed
3,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide142$177,071
OzempicSemaglutide112$164,877
TymlosAbaloparatide46$155,764
JardianceEmpagliflozin126$128,592
EliquisApixaban94$85,656
FarxigaDapagliflozin Propanediol39$39,437
Synjardy XrEmpagliflozin/Metformin Hcl27$34,231
JanuviaSitagliptin Phosphate30$26,617
Evenity (2 Syringes)Romosozumab-Aqqg11$25,028
TrulicityDulaglutide18$24,145
Janumet XrSitagliptin Phos/Metformin Hcl30$22,743
Repatha SureclickEvolocumab27$21,987
XareltoRivaroxaban35$18,783
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,815
Breo ElliptaFluticasone/Vilanterol14$12,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$932$201,216160 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$287$167,590164 claims
Novo NordiskOzempic$1,167$164,877112 claims
Radius Health, Inc.Tymlos$246$155,76446 claims
PfizerEliquis$334$85,65694 claims
MerckJanuvia, Janumet Xr$150$49,36060 claims
AstraZenecaFarxiga$438$39,43739 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$323$34,93949 claims
AmgenEvenity (2 Syringes)$831$25,02811 claims
Johnson & JohnsonXarelto$44$18,78335 claims
AbbVieSynthroid$199$3,04334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →